Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16423615 | 0.80 | LMNA (0.58) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1769439 | 0.77 | ALDH1A1 (0.47) | SMN1; SMN2KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL20588981 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2KMT2APKMMEN1ALDH1A1 | |
| SCHEMBL23011158 | 0.76 | LMNA (0.53) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL23011352 | 0.72 | NPC1 (0.46) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1769341 | 0.71 | LMNA (0.64) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1531369 | 0.70 | SMN1; SMN2 (0.49) | SMN1; SMN2KMT2APKMMEN1ALDH1A1 | |
| SCHEMBL5925521 | 0.70 | MAPT (0.62) | SMN1; SMN2KMT2APKMMEN1ALDH1A1 | |
| SCHEMBL20790150 | 0.69 | OPRM1 (0.50) | SMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL23011118 | 0.69 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11458124-B2 | Spirocyclic indane analogues as IL-17 modulators | UCBBiopharma Srl (BE) | 2022-10-04 | — | — | US | disclosed |
| US-20210228547-A1 | Spirocyclic Indane Analogues as IL-17 Modulators | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2021-07-29 | — | — | US | disclosed |
| CN-112334192-A | Spirocyclic indane analogs as IL-17 modulators | UCB生物制药有限责任公司 | 2021-02-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228547-A1 | Spirocyclic Indane Analogues as IL-17 Modulators | IL17A, IL18, IL23R | SMN1; SMN2 4236/4885KMT2A 4139/4885PKM 3491/4885 |
| US-11458124-B2 | Spirocyclic indane analogues as IL-17 modulators | IL17A, IL18, IL23R | SMN1; SMN2 4236/4885KMT2A 4139/4885PKM 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.